Nifedipine versus placebo in the treatment of preterm prelabor rupture of membranes: a randomized controlled trial: Assessment of perinatal outcome by use of tocolysis in early labor—APOSTEL IV trial

Tobias A J Nijman, Elvira O G van Vliet, Christiana A. Naaktgeboren, Katrien Oude Rengerink, Thomas S. de Lange, Caroline J. Bax, Kitty W M Bloemenkamp, Jim van Eyck, Marjolein Kok, Hubertina C J Scheepers, Mallory Woiski, Arie Franx, Ben Willem J Mol, Martijn A. Oudijk

Research output: Contribution to journalArticlepeer-review

16 Citations (Scopus)


Objective Preterm birth is the most common cause of neonatal morbidity and mortality. Around one third of preterm deliveries starts with preterm prelabor rupture of membranes (PPROM). The aim of this trial was to study the effect of prolonged tocolysis with nifedipine versus placebo in women with PPROM on perinatal outcome and prolongation of pregnancy. Study design The Apostel IV was a nationwide multicenter randomized placebo controlled trial. We included women with PPROM without contractions between 24 +0 and 33 +6 weeks of gestation. Participants were randomly allocated to daily 80 mg nifedipine or placebo, until the start of labor, with a maximum of 18 days. The primary outcome measure was a composite of poor neonatal outcome, including perinatal death, bronchopulmonary dysplasia, periventricular leukomalacia > grade 1, intraventricular hemorrhage > grade 2, necrotizing enterocolitis > stage 1 and culture proven sepsis. Secondary outcomes were gestational age at delivery and prolongation of pregnancy. Analysis was by intention to treat. To detect a reduction of poor neonatal outcome from 30% to 10%, 120 women needed to be randomized. Trial registry: NTR 3363. Results Between October 2012 and December 2014 we randomized 25 women to nifedipine and 25 women to placebo. Due to slow recruitment the study was stopped prematurely. The median gestational age at randomization was 29.9 weeks (IQR 27.7–31.3) in the nifedipine group and 27.0 weeks (IQR 24.7–29.9) in the placebo group. Other baseline characteristics were comparable. The adverse perinatal outcome occurred in 9 neonates (33.3%) in the nifedipine group and 9 neonates (32.1%) in the placebo group (RR 1.04, 95% CI 0.49–2.2). Two perinatal deaths occurred, both in the nifedipine group. Bronchopulmonary dysplasia was seen less frequently in the nifedipine group (0% versus 17.9%; p = 0.03). Prolongation of pregnancy did not differ between the nifedipine and placebo group (median 11 versus 8 days, HR 1.02; 95% CI 0.58–1.79). Conclusion This randomized trial did not show a beneficial effect of prolonged tocolysis on neonatal outcomes or prolongation of pregnancy in women with PPROM without contractions. However, since results are based on a small sample size, a difference in effectiveness cannot be excluded.

Original languageEnglish
Pages (from-to)79-84
Number of pages6
JournalEuropean Journal of Obstetrics and Gynecology and Reproductive Biology
Publication statusPublished or Issued - 1 Oct 2016


  • Drug safety
  • Neonatal outcomes
  • Nifedipine
  • Preterm birth
  • Preterm prelabor rupture of membranes
  • Tocolytics

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynaecology

Cite this